

REMARKS

Formal Matters

Formal drawings Figures 1A-1B, 2A-2C, 3A-3B, 4A-4C, 5A-5C, 6, 7A-7D, 8A-8B, 9A-9B and 10 are submitted herewith.

Claims 34-87 are added by amendment herewith to this application. Claims 1-33 have been canceled.

Support for polypeptide claims 34-38 appears at least as follows: (1) polypeptide variants in general at page 17, line 8 through page 22, line 2; (2) Insertion variants at page 19, line 18 to page 20, line 1; (3) Deletion variants at page 19, lines 2-17; (4) Substitution variants at page 20, line 2 to page 22, line 5.

Support for polypeptide claims 39-42 appears at least as follows: page 5, lines 13-19 (description of Figure 2); Figure 2; page 6, lines 9-12 (description of Figure 6; Figure 6; page 19, line 23 to page 20 line 1.

Support for composition claims 43-44, 83-87 appears at least at page 44, lines 10-14.

Support for nucleic acid, vector, host cell and method using nucleic acid claims 45-66 appears at least at page 4, lines 17-26; page 13, lines 1-15.

Support for method claims 65-66 appear at least page 4, lines 17-19; page 16 lines 15-20; page 37, line 17 to page 38, line 12.

Support for antibody claims 69-82 appears at least at page 3, line 20 to page 4, line 7; page 10, line 19 to page 11, line 3.

Support for polyclonal and monoclonal antibody claims 70, 71 and 76, 77, 79, 81 appears at least at page 47, line 25 to page 48, line 7.

Support for IgG1 isotype antibody claims 72, 78, 80, 82 appears at least at page 19, lines 6-10.

Support for antibody Claims 73-75 appears at least at page 3, lines 14-19; page 5, lines 13-19 (description of Figure 2); Figure 2; page 6, lines 9-12 (description of Figure 6; Figure 6; page 19, line 23 to page 20 line 1.

In view of the Examiner's earlier restriction requirement, applicant retains the right to present the subject matter of cancelled claims 1-33 in a divisional or continuation application.

SUMMARY

New claims 34-87 are pending in the application. Claims 1-33 are canceled without prejudice to later prosecution.

If in the opinion of the Examiner, a **telephone conference** would expedite the prosecution of the subject application, the Examiner is **strongly encouraged** to call the undersigned at the number indicated below.

This response/amendment is submitted with a transmittal letter and petition for a 4-month extension of time and fees. In the unlikely event that this document is separated from the transmittal letter or if fees are required, applicants petition the Commissioner to authorize charging our Deposit Account 07-0630 for any fees required or credits due and any extensions of time necessary to maintain the pendency of this application.

Applicants respectfully request that a timely Notice of Allowance be issued in this case.

Respectfully submitted,

GENENTECH, INC.

Date: September 19, 2003

By: 

Craig G. Svoboda

Reg. No. 39,044

Telephone No. (650) 225-1489